Phase II trial

Woman standing on scales
#Adverse event #Obesity #Phase II trial #Viking Therapeutics #Weight loss

Mixed top-line results for Viking’s oral obesity drug

Viking Therapeutics has released positive top-line results from its Phase II clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.   VK2735 is being developed in both oral and subcutaneous formulations for… Read More

#News #Trending News

Neurons in Parkinson's disease
#Neuroinflammation #Neuroscience #NodThera #Parkinson's #Phase II trial

Oral NLRP3 inhibitor reverses neuroinflammation in Parkinson’s

NodThera has shared positive data from its Parkinson’s disease Phase Ib/IIa study evaluating the effects of NT-0796, its oral, brain-penetrant NLRP3 inflammasome inhibitor.  In the first publication to demonstrate the clinical potential of an oral, fully brain-penetrant NLRP3 inhibitor in Parkinson’s disease, NT-0796 was shown to be… Read More

#News

Laboratory research
#Clinical trial #Faron Pharmaceuticals #Oncology #Phase II trial

Faron reports 43% complete remission rate in MDS

Faron Pharmaceuticals has announced an increase in the complete remission (CR) rate in patients with frontline or treatment-naïve high-risk myelodysplastic syndrome (HR-MDS), based on updated efficacy data from its Phase I/II BEXMAB trial.  According to the investigator-assessed response using IWG 2006 criteria, as per protocol, the CR… Read More

#News

Patient receiving eye drops
#Exonate #Ophthalmology #Phase II trial

Plans for Phase IIb trial of EXN407 for diabetic eye disease

Exonate has announced plans to initiate a Phase IIb clinical trial for its lead candidate, EXN407. The Clinical Evaluation of a New Eye Drop for Alleviating Retinopathy in Diabetic Eye Disease (CLEAR-DE) trial will further evaluate the clinical efficacy, optimal dosing and safety profile of EXN407 in patients… Read More

#News

Lungs
#Idiopathic pulmonary fibrosis #Lung disease #Phase II trial #Trevi Therapeutics

Drug significantly reduces common cough in IPF patients

Trevi Therapeutics has announced positive topline results from its Phase IIb CORAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF).   The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all… Read More

#News

Bone cancer
#Immunotherapy #Oncology #OS Therapies #Osteosarcoma #Phase II trial #Rare disease

One-year event free survival reported at osteosarcoma conference

OS Therapies has shared positive clinical trial data updates from its Phase IIb clinical trial of immunotherapy candidate OST-HER2 in fully resected, lung metastatic osteosarcoma.  The data were presented by Principal Investigator Dr Damon Reed at the MIB Factor Osteosarcoma Conference held in Salt Lake City, Utah… Read More

#Cancer Research #News

Human heart
#Cardiovascular disease #Cell therapy #Longeveron #Paediatrics #Phase II trial #Regenerative Medicine

Regenerative cell therapy for rare heart disease enters PhII trials

Longeveron has completed enrolment for its Phase IIb clinical trial (ELPIS II) evaluating cellular therapy laromestrocel as a potential adjunct treatment for Hypoplastic Left Heart Syndrome (HLHS).  Laromestrocel is a scalable, allogeneic cellular therapy being evaluated in multiple indications.  Top-line trial results are anticipated in… Read More

#News

Palmoplantar Pustulosis
#Dermatology #JAK inhibitor #LEO Pharma #Phase II trial #Rare disease

Phase IIa trial assesses delgocitinib cream in rare skin disease

LEO Pharma has initiated the Phase IIa proof-of-concept DELTA NEXT trial to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle for mild to severe Palmoplantar Pustulosis (PPP).  “The DELTA NEXT trial in PPP represents an exciting new chapter in the clinical development journey… Read More

#News

#Deep learning #Idiopathic pulmonary fibrosis #Imaging #Phase II trial #Qureight

Deep-learning imaging technology to enhance Phase II trial

Biopharmaceutical company Rein Therapeutics and core imaging laboratory Qureight have announced plans to collaborate on an idiopathic pulmonary fibrosis (IPF) clinical trial.  The companies will integrate Qureight’s deep-learning platform into Rein’s planned Phase II trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide.  … Read More

#News

#Clinical trials #Diabetes #Multiple sclerosis #Oncology #Phase II trial #Phase III trial

New DDW Highlights podcast: 28 April 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With Eli Lilly so far winning the race to bring an oral GLP-1 drug… Read More

#News

Red blood cells
#Bioxodes #Phase II trial #Stroke

Positive data for intracerebral haemorrhagic stroke drug

Bioxodes has shared promising interim results from the BIRCH Phase IIa clinical trial of its lead asset, BIOX-101, to treat intracerebral haemorrhagic stroke (ICH).  Interim analysis from the first 16 patients in the trial showed that primary safety and secondary efficacy endpoints were met.   “While… Read More

#News

#Clinical trials #Diabetes #Multiple sclerosis #Oncology #Phase II trial #Phase III trial

This week in drug discovery (21-25 April) 

News round-up for 21-25 April by DDW Senior Digital Content Editor Diana Spencer. With Eli Lilly so far winning the race to bring an oral GLP-1 drug to market, having announced positive topline results from a Phase III trial, this week our news highlights focus on clinical studies. Read More

#News

Monoclonal antibodies
#Monoclonal antibodies #Multiple sclerosis #Phase II trial #Tiziana Life Sciences #University of Massachusetts

UMass joins Phase II trial for multiple sclerosis

The University of Massachusetts (UMass) has begun dosing participants with Tiziana Life Sciences’ lead development candidate, intranasal foralumab, as part of an ongoing Phase II trial in patients with non-active secondary progressive multiple sclerosis (na-SPMS). UMass joins Brigham and Women’s Hospital (BWH), Yale Multiple Sclerosis Center, and Johns… Read More

#News

CAR-T therapy
#CAR-T #Cell therapy #Haematology #Lymphoma #March Biosciences #Phase II trial

Phase II trial starts for CAR-T therapy in T-cell lymphoma

March Biosciences (March Bio) announced that the first patient has been dosed in its Phase II clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.   “This represents a significant milestone in advancing MB-105 as a potential treatment… Read More

#Cancer Research #News

Melanoma
#Aulos Bioscience #Melanoma #Monoclonal antibodies #Oncology #Phase II trial

Aulos doses first patient in Phase II cohort for melanoma treatment

Aulos Bioscience has dosed its first patient with a combination of AU-007, the anti-PD-1 antibody nivolumab and low-dose, subcutaneous aldesleukin in a Phase II expansion cohort focused on second-line treatment of melanoma.   The new cohort forms part of the company’s Phase I/II clinical trial of AU-007… Read More

#Cancer Research #News